Author

Drew A. Harrison

Harvard UniversityORCID 0009-0009-5232-0640Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Systems Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:proteomics· 2

Frequent Co-Authors

Ann-Sophie Koglin· 2 shared Christopher J. OttiD· 2 shared Samuel OjedaiD· 2 shared Aaron N. HataiD· 1 shared Adam AckeriD· 1 shared Aleigha R. LawlessiD· 1 shared Alexander Healy· 1 shared Aliyu Sidi Omar Alghali· 1 shared

Activity by Year

2024-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 39 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Ann-Sophie Koglin

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologyCell chemical biologyPeer-reviewedMar 29, 2025

Targeted Degradation of CDK9 Potently Disrupts the MYC Transcriptional Network

Mohammed A. Toure, Keisuke Motoyama, Yichen Xiang…·Angela N. Koehler

This study shows that CDK9 degradation with KI-CDK9d-32 is more effective than inhibition in disrupting MYC transcriptional networks and causes MYC downregulation and nucleolar destabilization.

22 citationstop 3%

humanproteomics

Systems BiologyCellPeer-reviewedApr 22, 2024

DrugMap: A quantitative pan-cancer analysis of cysteine ligandability

Mariko Takahashi, Harrison Byron Chong, Siwen Zhang…·Liron Bar‐Peled

DrugMap quantitatively analyzes cysteine ligandability across 416 cancer cell lines, revealing redox state, conformational changes, and mutations as drivers of variability, and identifies covalent inhibitors targeting NFκB1 and SOX10.

106 citationstop 1%

humanproteomics